Laurie D. Snyder

Laurie D. Snyder

Auto-generated profile, based on publicly available information

Laurie D. Snyder

Division of Pulmonary Allergy and Critical Care Medicine Department of Medicine Duke University Medical Center Durham North Carolina USA

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2016 in The Journal of Heart and Lung Transplantation
Verified
Journal Article
Closed access
DLDeborah J. Levine
Deborah J. Levine
AGAllan R. Glanville
Allan R. Glanville
CAChristina Aboyoun
Christina Aboyoun
JBJohn Belperio
John Belperio
CBChristian Benden
Christian Benden
AZAdriana Zeevi
Adriana Zeevi

30 March 2018 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
ATAnat R. Tambur
Anat R. Tambur
PCPatricia Campbell
Patricia Campbell
FCFrans H. Claas
Frans H. Claas
SFSandy Feng
Sandy Feng
HGHoward M. Gebel
Howard M. Gebel
PNPeter Nickerson
Peter Nickerson
The presence of preexisting (memory) or de novo donor‐specific HLA antibodies (DSAs) is a known barrier to successful long‐term organ transplantation. Yet, despite the fact that laboratory tools and our understanding of histocompatibility have advanced significantly in recent years, the criteria to define presence of a DSA and assign a level of risk for a given DSA vary markedly between centers. A collaborative effort between the American Society for Histocompatibility and Immunogenetics and the American Society of Transplantation provided the logistical support for generating a dedicated multidisciplinary working group, which included experts in histocompatibility as well as kidney, liver, heart, and lung transplantation. The goals were to perform a critical review of biologically driven, state‐of‐the‐art, clinical diagnostics literature and to provide clinical practice recommendations based on expert assessment of quality and strength of evidence. The results of the Sensitization in Transplantation: Assessment of Risk (STAR) meeting are summarized here, providing recommendations on the definition and utilization of HLA diagnostic testing, and a framework for clinical assessment of risk for a memory or a primary alloimmune response. The definitions, recommendations, risk framework, and highlighted gaps in knowledge are intended to spur research that will inform the next STAR Working Group meeting in 2019.

1 November 2018 in Chest
Verified
Journal Article
Open access
SPScott M. Palmer
Scott M. Palmer
LSLaurie Snyder
Laurie Snyder
JTJamie L. Todd
Jamie L. Todd
BSBenjamin Soule
Benjamin Soule
RCRose Christian
Rose Christian
GRGlenn Rosen
Glenn Rosen
Idiopathic pulmonary fibrosis (IPF) causes irreversible loss of lung function. The lysophosphatidic acid receptor 1 (LPA1) pathway is implicated in IPF etiology. Safety and efficacy of BMS-986020, a high-affinity LPA1 antagonist, was assessed vs placebo in a phase 2 study in patients with IPF. IM136003 was a phase 2, parallel-arm, multicenter, randomized, double-blind, placebo-controlled trial. Adults with IPF (FVC, 45%-90%; diffusing capacity for carbon monoxide, 30%-80%) were randomized to receive placebo or 600 mg BMS-986020 (once daily [qd] or bid) for 26 weeks. The primary end point was rate of change in FVC from baseline to week 26. Of 143 randomized patients, 108 completed the 26-week dosing phase. Thirty-five patients discontinued prematurely. Patient baseline characteristics were similar between treatment groups (placebo: n = 47; 600 mg qd: n = 48; 600 mg bid: n = 48). Patients treated with BMS-986020 bid experienced a significantly slower rate of decline in FVC vs placebo (-0.042 L; 95% CI, -0.106 to -0.022 vs -0.134 L; 95% CI, -0.201 to -0.068, respectively; P = .049). Dose-related elevations in hepatic enzymes were observed in both BMS-986020 treatment groups. The study was terminated early because of three cases of cholecystitis that were determined to be related to BMS-986020 after unblinding. BMS-986020 600 mg bid treatment for 26 weeks vs placebo significantly slowed the rate of FVC decline. Both regimens of BMS-986020 were associated with elevations in hepatic enzymes. ClinicalTrials.gov; No.: NCT01766817; URL: www.clinicaltrials.gov.

15 May 2014 in European Respiratory Journal
Verified
Journal Article
Open access
PDF file
LSLeann L. Silhan
Leann L. Silhan
PSPali D. Shah
Pali D. Shah
DCDaniel C. Chambers
Daniel C. Chambers
LSLaurie D. Snyder
Laurie D. Snyder
GRGerdt C. Riise
Gerdt C. Riise
MAMary Armanios
Mary Armanios
Lung transplantation is the only intervention that prolongs survival in idiopathic pulmonary fibrosis (IPF). Telomerase mutations are the most common identifiable genetic cause of IPF, and at times, the telomere defect manifests in extrapulmonary disease such as bone marrow failure. The relevance of this genetic diagnosis for lung transplant management has not been examined.We gathered an international series of telomerase mutation carriers who underwent lung transplant in the USA, Australia and Sweden.The median age at transplant was 52 years. Seven recipients are alive with a median follow-up of 1.9 years (range 6 months to 9 years); one died at 10 months. The most common complications were haematological, with recipients requiring platelet transfusion support (88%) and adjustment of immunosuppressives (100%). Four recipients (50%) required dialysis for tubular injury and calcineurin inhibitor toxicity. These complications occurred at significantly higher rates relative to historic series (p<0.0001).Our observations support the feasibility of lung transplantation in telomerase mutation carriers; however, severe post-transplant complications reflecting the syndromic nature of their disease appear to occur at higher rates. While these findings need to be expanded to other cohorts, caution should be exercised when approaching the transplant evaluation and management of this subset of pulmonary fibrosis patients.

15 June 2010 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Closed access
LSLaurie D. Snyder
Laurie D. Snyder
CFC. Ashley Finlen-Copeland
C. Ashley Finlen-Copeland
WTW. Jackson Turbyfill
W. Jackson Turbyfill
DHDavid Howell
David Howell
DWDaniel A. Willner
Daniel A. Willner
SPScott M. Palmer
Scott M. Palmer
Rationale: Cytomegalovirus pneumonitis is one of the most prevalent opportunistic infections after lung transplantation. Early studies reported that cytomegalovirus pneumonitis was a risk factor for chronic allograft dysfunction. More recently, in the era of routine prophylaxis and ganciclovir treatment, the adverse impact of treated cytomegalovirus pneumonitis on bronchiolitis obliterans syndrome has been challenged. Objectives: We hypothesized that cytomegalovirus pneumonitis contributes to adverse outcomes in the current antiviral era. We sought to define the impact of treated cytomegalovirus pneumonitis on bronchiolitis obliterans syndrome and survival in a large single-center cohort (n = 231) of consecutive patients undergoing lung transplantation from 2000 to 2004, all receiving short-course ganciclovir prophylaxis. Methods: Transbronchial biopsies were performed at defined intervals with prospective cytomegalovirus immunostaining on every biopsy (n = 1,887). Cox proportional hazards models were used to assess the relationship between treated cytomegalovirus pneumonitis and clinical outcomes. Measurements and Main Results: Forty-nine (21%) recipients developed cytomegalovirus pneumonitis a median of 106 days after transplantation. Treated cytomegalovirus pneumonitis within the first 6 months after transplantation significantly increased the risk for bronchiolitis obliterans syndrome (P = 0.001; hazard ratio, 2.19; 95% confidence interval, 1.36–3.51) and post-transplantation death (P = 0.02; hazard ratio, 1.89; 95% confidence interval, 1.11–3.23). This risk persisted when cytomegalovirus pneumonitis was considered as a time-dependent predictor as well as in multivariable models controlling for other risk factors. Conclusions: Cytomegalovirus pneumonitis affects more than 20% of lung transplant recipients. Despite treatment, it increases the risk for bronchiolitis obliterans syndrome and death. More effective preventive strategies for cytomegalovirus pneumonitis are needed to improve long-term outcomes after lung transplantation.

1 August 2011 in The Annals of Thoracic Surgery
Verified
Journal Article
Closed access
MHMatthew G. Hartwig
Matthew G. Hartwig
DADeverick J. Anderson
Deverick J. Anderson
MOMark W. Onaitis
Mark W. Onaitis
SRShekur Reddy
Shekur Reddy
LSLaurie D. Snyder
Laurie D. Snyder
RDR. Duane Davis
R. Duane Davis